Ulcerative Colitis: Update Bulletin #2 [March 2018]
This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include; Celgene reporting data from a Phase II trial of Otezla (apremilast) in patients with UC; Protalix BioTherapeutics announcing final dosing of the last patient in a Phase II trial evaluating OPRX 106, an oral anti-TNF, in patients with UC; and Pfizer announcing a positive outcome from a US Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting regarding Xeljanz (tofacitinib) for the treatment of moderate to severe UC.
Business Questions:
Business Questions:
- According to KOLs, how clinically attractive is Otezla (apremilast) as a treatment for UC?
- What are the experts’ views on Otezla’s Phase II data?
- If approved, where would Otezla be positioned in the UC treatment paradigm?
- What do KOLs think of OPRX 106 as a therapy for UC?
- Do KOLs have any concerns regarding OPRX 106?
- What are KOLs’ reactions to the positive FDA outcome regarding Xeljanz (tofacitinib)?
- If approved, how is Xeljanz expected to be used in the UC treatment algorithm?
